• The European Union (EU) marketing authorisation for the subcutaneous (SC) formulation of Remsima^??(CT-P13) now applies to all previously approved indications for the intravenous (IV) formulation in adult patients including: ankylosing spondylitis (AS), Crohn?s disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis (PsO)
• The EU marketing authorisation is based on pivotal data comparing the pharmacokinetics, efficacy and safety of the IV and SC formulations of Remsima^??in people with active CD and UC
• Celltrion?s Remsima^??SC is the first and only infliximab to have both IV and SC formulations; Remsima^??SC reduces treatment time to approximately 2-5 minutes, with a comparable efficacy and safety profile to the IV formulation of Remsima^?

July 27, 2020 07:38 AM Eastern Daylight Time

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima^??(infliximab, CT-P13) subcutaneous (SC) formulation for the treatment of adult patients with ankylosing spondylitis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis.¹ The approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June and is based on data from a pivotal study comparing the pharmacokinetics, efficacy and safety of the SC and intravenous (IV) formulations of Remsima^??in people with active Crohn?s disease and ulcerative colitis, throughout a 1-year treatment period.^2,3?Based on the results of the pivotal study, a 120 mg fixed dose of Remsima^??SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications. Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany said: ?The subcutaneous formulation of Remsima^??(Remsima^??SC) has been shown to have very high efficacy, and favourable data, which are fully comparable to the efficacy and safety profile of the IV formulation. Today?s approval marks an important progress for the gastroenterology community as it means that treatment can now be administered in significantly less time, thereby providing patients more flexibility and control over how they receive their treatment.? ?We are pleased to announce this important regulatory milestone earlier than we expected, with the European Commission prioritising review of this important new administration option. We will accelerate the launch process on a country-by-country basis in order to expand treatment options for patients with chronic inflammatory diseases such as inflammatory bowel disease and ankylosing spondylitis,? said Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. ?We will do our best to make Remsima^??SC available as early as possible and hope this medication will contribute to minimising the risks involved with administering medical treatments during the COVID-19 pandemic.? Celltrion anticipates receiving approval of Remsima^??SC in 97 countries, including 31 countries in Europe.

-- ENDS --

Notes to Editors: About Remsima^??(CT-P13) intravenous (IV) formulation¹ Remsima^??IV is usually given as 3 mg per kg/body weight in rheumatoid arthritis (RA) and as 5 mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards. About Remsima^??CT-P13 subcutaneous (SC) formulation^4,5 A 120 mg fixed dose of Remsima^??SC has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications for the IV formulation. Remsima^??SC has three administration options; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard. The SC formulation has the potential to enhance treatment options for the use of infliximab biosimilar by providing high consistency in drug exposure and a convenient method of administration. About CT-P13 (biosimilar infliximab) CT-P13 is developed and manufactured by Celltrion, Inc. and was the world?s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including RA and IBD. It was approved by the EC under the trade name Remsima^??in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra^?. CT-P13 is approved in more than 94 countries (as of July 2020) including the US, Canada, Japan and throughout Europe. About Celltrion Healthcare Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients? access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit:?https://www.celltrionhealthcare.com/en-us Forward-looking statement disclaimer Certain information set forth in this press release contains statements related to our future business and financial performance, and future events or developments involving Celltrion Healthcare, that may constitute forward-looking statements, under pertinent securities laws. These statements may be identified by words such as ?will?, ?has potential to?, ?brings?, ?if approved?, ?would?, ?could?, ?opportunity?, ?hope?, ?is considering? the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Healthcare's management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management?s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management?s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. References ¹?European Medicines Agency Summary of Product Characteristics (SmPC). Remsima. ²?Reinisch W,?et al.?A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase 1 open-label randomised controlled trial in patients with active Crohn?s disease. European Crohn?s and Colitis Organisation 2019. Abstract no: A-1103. ³?Ben-Horin S,?et al.?A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn?s disease and ulcerative colitis. Oral presentation (OP24). Presented at ECCO 2020. ⁴?Yoo DH, Jaworski J, Matyska-Piekarska E?et al.?A Novel Formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: One-year results from part one of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (FRI0128). Presented at EULAR 2019. ⁵?Westhovens R, Wiland P, Zawadzki M?et al.?A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (SAT0170). Presented at EULAR 2019.